Lv5
830 积分 2025-12-15 加入
A phase 1 feasibility trial of BE-CAR33, an “off-the-shelf” base-edited CAR33 T cell therapy for acute myeloid leukemia
15天前
已完结
A bispecific CD3×CD19 antibody for systemic lupus erythematosus: a phase 1 trial
24天前
已完结
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis
1个月前
已完结
Tumor CD19 Expression Determines Distinct Clinical Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma
1个月前
已完结
Response kinetics following CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry
1个月前
已完结
Dual MYC and GSPT1 Protein Degrader for MYC-Driven Hematologic Malignancies
1个月前
已完结
Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma
1个月前
已完结
Promises and potential pitfalls of in vivo CAR gene therapy
1个月前
已完结
Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study
1个月前
已完结
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
2个月前
已完结
皖公网安备34019202002308
